Akanksha IVF Centre Leads Breakthrough Study on PRP Therapy for Thin Endometrium
PRP Therapy Enhances Endometrial Receptivity in Women with Thin Endometrium: A Breakthrough Study
Introduction
Infertility affects a significant percentage of the global population, and advances in assisted reproductive technology (ART) have offered various solutions. However, one persistent issue faced by women undergoing IVF (In Vitro Fertilization) is implantation failure, often due to a thin endometrium. The endometrium, or uterine lining, plays a crucial role in embryo implantation. If the endometrial lining is too thin, the chances of a successful implantation are dramatically reduced.
For years, doctors have been searching for methods to enhance the endometrial thickness in such patients, leading to the development of various treatments. One such promising treatment is Platelet-Rich Plasma (PRP) therapy, which is now being increasingly explored for its potential to improve endometrial receptivity.
A recent study published in the European Journal of Obstetrics & Gynecology has brought new hope to women struggling with thin endometrium and repeated IVF cycle failures. The research conducted at Akanksha IVF Centre in New Delhi demonstrated that intrauterine PRP therapy significantly improved endometrial thickness and pregnancy outcomes in women undergoing frozen embryo transfer (FET) cycles.
Study Overview
The study, titled "Platelet-rich plasma therapy enhances endometrial receptivity in thin endometrium patients undergoing frozen embryo transfer cycles: results from a prospective cohort observational study", was led by Dr. K.D. Nayar, Dr. Shweta Arora, Dr. Sabina Sanan, Dr. Manika Sachdeva, Dr. Kapil Nayar, Dr. Gaurav Kant, and Dr. Ankita Sethi. It was conducted between August 1, 2023, and July 31, 2024, at Akanksha IVF Centre, and included 100 patients under 40 years of age who had a thin endometrium (measuring less than 7mm on transvaginal ultrasound).
The patients were divided into two groups:
-
PRP Group: 70 women received intrauterine PRP therapy on days 7, 9, and 11 of their menstrual cycle.
-
Control Group: 30 women did not receive the PRP therapy.
Key Findings
-
Endometrial Thickness Improvement: The PRP group showed a statistically significant increase in endometrial thickness compared to the control group. The mean increase in endometrial thickness was 7.305 ± 0.746 mm in the PRP group, compared to 5.72 ± 0.84 mm in the non-PRP group, a p-value of 0.032 indicating a clear enhancement.
-
Clinical Pregnancy Rate: The clinical pregnancy rate was notably higher in the PRP group at 35.71%, compared to just 10% in the control group. This result highlights the efficacy of PRP therapy in improving implantation success.
-
Safety and Tolerance: PRP therapy was safe and well-tolerated, with no adverse reactions reported during the study, making it a promising adjunct treatment for women with thin endometrium.
The Science Behind PRP Therapy
Platelet-Rich Plasma (PRP) is derived from the patient's own blood. By centrifuging a blood sample, platelets are concentrated to 4–5 times their normal concentration. When PRP is injected into the uterine lining, the platelets release growth factors that promote tissue repair and angiogenesis (formation of new blood vessels), which are essential for a healthy, receptive endometrium.
PRP is believed to work through several mechanisms:
-
Angiogenesis: PRP promotes the formation of new blood vessels, improving the blood flow to the endometrium, which is crucial for nutrient supply and growth.
-
Fibrosis Reduction: PRP therapy helps reduce fibrosis in the endometrial lining, which is often a result of previous surgeries or inflammation.
-
Cellular Regeneration: The growth factors in PRP stimulate fibroblasts, epithelial cells, and mesenchymal stem cells, promoting endometrial regeneration and thickening.
-
Anti-inflammatory Effects: PRP also has anti-inflammatory properties, which could be particularly beneficial for women suffering from endometrial damage due to conditions like genital tuberculosis or previous uterine surgeries.
Implications for IVF Treatment
The results of this study offer significant hope for women who have experienced repeated IVF cycle cancellations due to inadequate endometrial development. Traditionally, hormone replacement therapy (HRT) has been the primary method for endometrial preparation, but PRP therapy appears to be a powerful complementary treatment, enhancing endometrial receptivity and improving clinical pregnancy rates.
For women with thin endometrium, PRP therapy represents a breakthrough, especially for those who have not responded well to conventional treatments. This therapy not only improves the chances of successful implantation but also provides a safer and more natural alternative to other invasive or synthetic treatments.
Conclusion
This study reinforces the role of PRP therapy as a valuable addition to the arsenal of treatments available for women with thin endometrium undergoing frozen embryo transfer cycles. The data suggests that PRP therapy can significantly improve endometrial thickness, promote a more receptive uterine environment, and enhance pregnancy outcomes, offering renewed hope to women who had previously faced repeated IVF failures.
With no significant side effects observed and a high success rate in improving pregnancy outcomes, PRP therapy has the potential to revolutionize the way clinicians manage thin endometrium in ART. This innovative approach could be a game-changer in the field of fertility treatments, helping many women achieve the dream of becoming mothers.
Read the Full Study
To explore the detailed findings and methodology, you can access the full study Full Article to read
For More Details:
Visit : www.akankshaivfcentre.com
IVF Centre Delhi Address:
Akanksha IVF Centre Delhi
A-3/7, Janakpuri,
New Delhi, India – 110058
Phone: +91-11-45682024
Mobile: +91-9810398765, 9810398767
Email: kdnayar@usa.net
IVF Hospital Delhi Address:
Akanksha IVF Centre Delhi
Room No. 628,
Mata Chanan Devi Hospital,
C-1, Janakpuri, New Delhi,
India – 110058
Phone: +91-11-45582228, +91-11-45582227, 2229
Mobile: +91-9810398765, 9810398767
Fax: +91-11-25622103
Email: kdnayar@usa.net
Comments
Post a Comment